In a report released yesterday, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Esperion (ESPR), with a price target of $112. The company’s shares opened today at $46.98.
Archila wrote:
“We are reiterating our Buy rating on shares after its 4Q18 business update. We view the upcoming Phase 2 results for BPA/ezetimibe in diabetic patients with high LDL-C as an interesting, but likely modest catalyst, while the outcome of BPA/combo’s advisory committee meeting, which probably occurs early next year (assuming a standard 10- month review after NDA acceptance) remains the major stock moving catalyst. With that said, we remain convicted on the commercial opportunity for BPA/combo (see deep dive) and while there is likely to be volatility in the stock over the first part of the year in 2019, we think the stock begins moving up as we get closer to the Adcom. We maintain our Buy rating and $112 target price.”
According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.1% and a 36.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Rhythm Pharmaceuticals Inc, and Selecta Biosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $93.80 average price target, a 99.7% upside from current levels. In a report issued on March 1, Northland Securities also maintained a Buy rating on the stock with a $65 price target.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $60.04 million. In comparison, last year the company had a GAAP net loss of $37.89 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
